Table 4 Initial versus final visual acuity in 141 eyes with documented visual acuity before and after treatment with ranibizumab. Group 1 includes the eyes approved by the national health insurance system on only one application. Group 2 includes the eyes approved on the second application (n = 26) or third application (n = 1).
From: Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Visual acuity | Total (n = 141) | Group 1 (n = 114) | Group 2 (n = 27) | |||
|---|---|---|---|---|---|---|
(logMAR) | Initial | Final | Initial | Final | Initial | Final |
Mean | 0.804 | 0.653 | 0.782 | 0.600 | 0.896 | 0.876 |
(Landolt C equivalent) | (0.157) | (0.222) | (0.165) | (0.251) | (0.127) | (0.133) |
SD | 0.349 | 0.486 | 0.352 | 0.459 | 0.328 | 0.542 |
P-value | <0.001 | <0.001 | 0.780 | |||
